Associations of tubal ligation and hysterectomy with serum androgen and estrogen metabolites among postmenopausal women in the Women's Health Initiative Observational Study.

Androgen metabolites Estrogen metabolites Hysterectomy Never hormone therapy users Postmenopausal Tubal ligation

Journal

Cancer causes & control : CCC
ISSN: 1573-7225
Titre abrégé: Cancer Causes Control
Pays: Netherlands
ID NLM: 9100846

Informations de publication

Date de publication:
21 May 2024
Historique:
received: 07 12 2023
accepted: 15 04 2024
medline: 22 5 2024
pubmed: 22 5 2024
entrez: 21 5 2024
Statut: aheadofprint

Résumé

Hysterectomy is associated with subsequent changes in circulating hormone levels, but the evidence of an association for tubal ligation is unclear. We evaluated whether circulating concentrations of androgens and estrogens differ by tubal ligation or hysterectomy status in postmenopausal women from the Women's Health Initiative (WHI)-Observational Study (OS). Serum androgens and estrogens were measured in 920 postmenopausal women who did not use menopausal hormone therapy at the time of blood draw, of whom 139 self-reported a history of tubal ligation and 102 reported hysterectomy (with intact ovaries). Geometric mean hormone concentrations (GMs) and 95% confidence intervals (CIs) associated with a history of tubal ligation or hysterectomy (ever/never), as well as time since procedures, were estimated using adjusted linear regression with inverse probability of sampling weights to account for selection. Circulating levels of 12 androgen/androgen metabolites and 20 estrogen/estrogen metabolites did not differ by tubal ligation status. Among women reporting prior hysterectomy compared to women without hysterectomy, we observed lower levels of several androgens (e.g., testosterone (nmol/L): GM While we did not observe associations between prior tubal ligation and postmenopausal circulating hormone levels, our findings support that prior hysterectomy was associated with lower circulating testosterone levels and higher levels of some estrogen metabolites, which may have implications for future hormone-related disease risks.

Identifiants

pubmed: 38772931
doi: 10.1007/s10552-024-01882-4
pii: 10.1007/s10552-024-01882-4
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Références

Nelson DB et al (2005) Tubal ligation does not affect hormonal changes during the early menopausal transition. Contraception 71(2):104–110
doi: 10.1016/j.contraception.2004.09.008 pubmed: 15707559
Hakverdi AU et al (1994) Changes in ovarian function after tubal sterilization. Adv Contracept 10(1):51–56
doi: 10.1007/BF01986530 pubmed: 8030455
J.C., D.K.A., Current contraceptive status among women aged 15–49: United States, 2015–2017. 2018, Hyattsville, MD: National Center for Health Statistics.
Barker MA (2016) Current issues with hysterectomy. Obstet Gynecol Clin North Am 43(3):591–601
doi: 10.1016/j.ogc.2016.04.012 pubmed: 27521886
QuickStats: Percentage of Women Aged ≥50 Years Who Have Had a Hysterectomy, by Race/Ethnicity and Year — National Health Interview Survey, United States, 2008 and 2018. MMWR Morb Mortal Wkly Rep 2019 2019; Available from: https://www.cdc.gov/mmwr/volumes/68/wr/mm6841a3.htm .
Greenwood S (1988) Hysterectomy and ovarian removal–a major health issue in the perimenopausal years. West J Med 149(6):771–772
pubmed: 3250119 pmcid: 1026642
Whiteman MK et al (2008) Inpatient hysterectomy surveillance in the United States, 2000–2004. Am J Obstet Gynecol 198(1):34.e1–7
doi: 10.1016/j.ajog.2007.05.039 pubmed: 17981254
Bulent Tiras M et al (2001) The changes in ovarian hormone levels and ovarian artery blood flow rate after laparoscopic tubal sterilization. Eur J Obstet Gynecol Reprod Biol 99(2):219–221
doi: 10.1016/S0301-2115(01)00410-9 pubmed: 11788175
Sørensen T et al (1981) Follicular stimulating hormone, luteinizing hormone and estrogen levels before and after female sterilization. Acta Obstet Gynecol Scand 60(6):559–561
doi: 10.3109/00016348109155486 pubmed: 6461157
McTiernan A et al (2008) Relation of demographic factors, menstrual history, reproduction and medication use to sex hormone levels in postmenopausal women. Breast Cancer Res Treat 108(2):217–231
doi: 10.1007/s10549-007-9588-6 pubmed: 18297397
Laughlin GA et al (2000) Hysterectomy, oophorectomy, and endogenous sex hormone levels in older women: the Rancho Bernardo Study. J Clin Endocrinol Metab 85(2):645–651
pubmed: 10690870
Horstman AM et al (2012) The role of androgens and estrogens on healthy aging and longevity. J Gerontol A Biol Sci Med Sci 67(11):1140–1152
doi: 10.1093/gerona/gls068 pubmed: 22451474 pmcid: 3636678
Labrie F et al (2003) Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr Rev 24(2):152–182
doi: 10.1210/er.2001-0031 pubmed: 12700178
Labrie F et al (2006) Androgen glucuronides, instead of testosterone, as the new markers of androgenic activity in women. J Steroid Biochem Mol Biol 99(4–5):182–188
doi: 10.1016/j.jsbmb.2006.02.004 pubmed: 16621522
Labrie F (2015) Intracrinology in action: importance of extragonadal sex steroid biosynthesis and inactivation in peripheral tissues in both women and men. J Steroid Biochem Mol Biol 145:131–132
doi: 10.1016/j.jsbmb.2014.09.012 pubmed: 25240498
Michels KA et al (2019) Postmenopausal androgen metabolism and endometrial cancer risk in the women’s health initiative observational study. JNCI Cancer Spectr. https://doi.org/10.1093/jncics/pkz029
doi: 10.1093/jncics/pkz029 pubmed: 31321379 pmcid: 6620792
Trabert B et al (2019) Circulating androgens and postmenopausal ovarian cancer risk in the Women’s Health Initiative Observational Study. Int J Cancer 145(8):2051–2060
doi: 10.1002/ijc.32157 pubmed: 30684389 pmcid: 6660427
Trabert B et al (2019) Circulating estrogens and postmenopausal ovarian and endometrial cancer risk among current hormone users in the Women’s Health Initiative Observational Study. Cancer Causes Control 30(11):1201–1211
doi: 10.1007/s10552-019-01233-8 pubmed: 31542834 pmcid: 6785392
Trabert B et al (2016) Circulating estrogens and postmenopausal ovarian cancer risk in the women’s health initiative observational study. Cancer Epidemiol Biomarkers Prev 25(4):648–656
doi: 10.1158/1055-9965.EPI-15-1272-T pubmed: 26908437 pmcid: 4873440
Brinton LA et al (2016) Serum estrogens and estrogen metabolites and endometrial cancer risk among postmenopausal women. Cancer Epidemiol Biomarkers Prev 25(7):1081–1089
doi: 10.1158/1055-9965.EPI-16-0225 pubmed: 27197275 pmcid: 4930692
Langer RD et al (2003) The Women’s Health Initiative Observational Study: baseline characteristics of participants and reliability of baseline measures. Ann Epidemiol 13(9 Suppl):S107–S121
doi: 10.1016/S1047-2797(03)00047-4 pubmed: 14575943
Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Control Clin Trials, 1998. 19(1): p. 61–109.
Oh H et al (2017) Anthropometric measures and serum estrogen metabolism in postmenopausal women: the Women’s Health Initiative Observational Study. Breast Cancer Res 19(1):28
doi: 10.1186/s13058-017-0810-0 pubmed: 28284224 pmcid: 5346241
Xu X et al (2007) Quantitative measurement of endogenous estrogens and estrogen metabolites in human serum by liquid chromatography-tandem mass spectrometry. Anal Chem 79(20):7813–7821
doi: 10.1021/ac070494j pubmed: 17848096
Rice MS, Murphy MA, Tworoger SS (2012) Tubal ligation, hysterectomy and ovarian cancer: A meta-analysis. J Ovarian Res 5(1):13
doi: 10.1186/1757-2215-5-13 pubmed: 22587442 pmcid: 3386864
Press DJ et al (2011) Breast cancer risk and ovariectomy, hysterectomy, and tubal sterilization in the women’s contraceptive and reproductive experiences study. Am J Epidemiol 173(1):38–47
doi: 10.1093/aje/kwq339 pubmed: 21109566
Nichols HB et al (2013) Tubal ligation in relation to menopausal symptoms and breast cancer risk. Br J Cancer 109(5):1291–1295
doi: 10.1038/bjc.2013.433 pubmed: 23922107 pmcid: 3778289
Brinton LA et al (2000) Tubal ligation and risk of breast cancer. Br J Cancer 82(9):1600–1604
pubmed: 10789731 pmcid: 2363387
Robinson WR et al (2016) Associations of premenopausal hysterectomy and oophorectomy with breast cancer among black and white women: the carolina breast cancer study, 1993–2001. Am J Epidemiol 184(5):388–399
doi: 10.1093/aje/kwv448 pubmed: 27555487 pmcid: 5013883
Chow S et al (2020) Breast cancer risk after hysterectomy with and without salpingo-oophorectomy for benign indications. Am J Obstet Gynecol 223(6):900.e1-900.e7
doi: 10.1016/j.ajog.2020.06.040 pubmed: 32585221
Ose J et al (2017) Androgens are differentially associated with ovarian cancer subtypes in the ovarian cancer cohort consortium. Cancer Res 77(14):3951–3960
doi: 10.1158/0008-5472.CAN-16-3322 pubmed: 28381542 pmcid: 5512110
Arthur RS, Dannenberg AJ, Rohan TE (2021) The association of prediagnostic circulating levels of cardiometabolic markers, testosterone and sex hormone-binding globulin with risk of breast cancer among normal weight postmenopausal women in the UK Biobank. Int J Cancer 149(1):42–57
doi: 10.1002/ijc.33508 pubmed: 33567105
Laughlin-Tommaso SK et al (2016) Cardiovascular risk factors and diseases in women undergoing hysterectomy with ovarian conservation. Menopause 23(2):121–128
doi: 10.1097/GME.0000000000000506 pubmed: 26173076 pmcid: 4712122
Michelsen TM et al (2023) All-cause and cardiovascular mortality after hysterectomy and oophorectomy in a large cohort (HUNT2). Acta Obstet Gynecol Scand 102(4):465–472
doi: 10.1111/aogs.14531 pubmed: 36814418 pmcid: 10008279
Howard BV et al (2005) Risk of cardiovascular disease by hysterectomy status, with and without oophorectomy: the Women’s Health Initiative Observational Study. Circulation 111(12):1462–1470
doi: 10.1161/01.CIR.0000159344.21672.FD pubmed: 15781742
Farland LV et al (2023) Hysterectomy with and without oophorectomy, tubal ligation, and risk of cardiovascular disease in the Nurses’ Health Study II. J Womens Health (Larchmt). https://doi.org/10.1089/jwh.2022.0207
doi: 10.1089/jwh.2022.0207 pubmed: 37155739
Ingelsson E et al (2011) Hysterectomy and risk of cardiovascular disease: a population-based cohort study. Eur Heart J 32(6):745–750
doi: 10.1093/eurheartj/ehq477 pubmed: 21186237
Coburn SB et al (2019) Comparability of serum, plasma, and urinary estrogen and estrogen metabolite measurements by sex and menopausal status. Cancer Causes Control 30(1):75–86
doi: 10.1007/s10552-018-1105-1 pubmed: 30506492
Jacoby VL et al (2010) Racial and ethnic disparities in benign gynecologic conditions and associated surgeries. Am J Obstet Gynecol 202(6):514–521
doi: 10.1016/j.ajog.2010.02.039 pubmed: 20430357 pmcid: 4625911

Auteurs

Ashley M Geczik (AM)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda, MD, USA. ag3895@drexel.edu.
Department of Environmental and Occupational Health, Dornsife School of Public Health, Drexel University, Philadelphia, PA, 19104, USA. ag3895@drexel.edu.

Kara A Michels (KA)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda, MD, USA.
Department of Epidemiology & Population Health, Albert Einstein College of Medicine, Bronx, NY, USA.

Garnet L Anderson (GL)

Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.

Roni T Falk (RT)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda, MD, USA.

Leslie V Farland (LV)

Department of Epidemiology and Biostatistics, Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ, USA.

JoAnn E Manson (JE)

Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.

Aladdin H Shadyab (AH)

Herbert Wertheim School of Public Health and Human Longevity Science, University of California - San Diego, La Jolla, CA, USA.

Ruth M Pfeiffer (RM)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda, MD, USA.

Xia Xu (X)

Cancer Research Technology Program, Leidos Biomedical Research, Inc, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.

Britton Trabert (B)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda, MD, USA.
Department of Obstetrics and Gynecology, University of Utah, Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT, USA.

Classifications MeSH